Current Report Filing (8-k)
July 17 2020 - 5:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT
REPORTED): July 17, 2020
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in
its Charter)
DELAWARE
|
001-37758
|
47-4671997
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
5300 Memorial Drive, Suite 950, Houston,
TX 77007
(Address of principal executive offices
and zip code)
(713) 300-5160
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
from last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-14(c)).
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
Common Stock, par value $.001 per share
|
MBRX
|
The NASDAQ Stock Market LLC
|
Item 1.01 Entry into a Material Definitive
Agreement.
On July 17, 2020, Moleculin Biotech, Inc.
(“Moleculin” or “Company”), entered into an At Market Issuance Sales Agreement (the “Agreement”)
with Oppenheimer & Co. Inc. (the “Agent”). Pursuant to the terms of the Agreement, the Company may sell from time
to time through the Agent shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) with
an aggregate sales price of up to $15.0 million (the “Shares”).
Any sales of Shares pursuant to the Agreement
will be made under the Company’s effective “shelf” registration statement (the “Registration Statement”)
on Form S-3 (File No. 333-235686), which became effective on April 9, 2020 and the related prospectus supplement and the accompanying
prospectus, as filed with the Securities and Exchange Commission (the “SEC”) on July 17, 2020.
Under the Agreement, the Company may sell
Shares through the Agent by any method that is deemed an “at the market offering” as defined in Rule 415 under the
Securities Act of 1933, as amended (the “Securities Act”).
Sales of the Shares, if any, may be made
at market prices prevailing at the time of sale, subject to such other terms as may be agreed upon at the time of sale, including
a minimum sales price that may be stipulated by the Company’s Board of Directors or a duly authorized committee thereof.
The Company or the Agent, under certain circumstances and upon notice to the other, may suspend the offering of the Shares under
the Agreement. The offering of the Shares pursuant to the Agreement will terminate upon the sale of Shares in an aggregate offering
amount equal to $15.0 million, or sooner if either the Company or the Agent terminate the Agreement pursuant to its terms.
The Company will pay a commission to the
Agent of 3.0% of the gross proceeds of the sale of the Shares sold under the Agreement and reimburse the Agent for certain expenses.
The Company has also provided the Agent with customary indemnification rights. The Company is not obligated to make any sales of
Common Stock under the Agreement.
The foregoing description of the Agreement
is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as Exhibit
1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Agreement is also incorporated by reference
into the Registration Statement.
A copy of the opinion of Schiff Hardin
LLP relating to the legality of the shares of Common Stock issuable under the Agreement is filed as Exhibit 5.1 to this Current
Report on Form 8-K and is also incorporated by reference into the Registration Statement.
The above disclosure shall not constitute
an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation,
or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
|
|
Date: July 17, 2020
|
|
|
|
By:
|
/s/ Jonathan P. Foster
|
|
|
Jonathan P. Foster
|
|
|
Chief Financial Officer
|
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Sep 2023 to Sep 2024